**Core tip:** This was a retrospective observational study to identify predictive markers for metachronous and synchronous gastric cancer (GC). Multivariate analysis revealed that higher age and the presence of gastric xanthoma were independently related to the development of metachronous and synchronous GC. Additional large prospective studies are necessary to investigate this important issue further.

INTRODUCTION
============

Endoscopic submucosal dissection (ESD) is currently accepted as an effective and minimally invasive treatment for early gastric cancer (GC)\[[@B1]-[@B7]\]. However, the development of metachronous and synchronous GC remains a possibility after ESD\[[@B8]-[@B14]\]. Predictive markers for the development of metachronous and synchronous GC have not been extensively studied. In addition, it is often difficult to clearly distinguish metachronous GC from synchronous GC because of missed detection of synchronous GC.

The cumulative incidence of metachronous GC after endoscopic resection for early GC ranges from 5.2% to 22.7%\[[@B8]-[@B14]\]. The incidence of missed detection of synchronous GC was reported to be between 1.2% and 7.7%\[[@B15],[@B16]\]. In 2015, the Kyoto global consensus report on *Helicobacter pylori* (*H. pylori*) gastritis was published\[[@B17]\]. At the same time, an endoscopic score for GC risk was also announced\[[@B18]\]. Also, gastric xanthoma (GX) has been reported as the predictive marker of early GC\[[@B19],[@B20]\].

The usefulness of endoscopic score for GC risk as an accurate predictor of GC risk remains unclear. And the utility of GX as a predictive marker of metachronous and synchronous GC also remains unknown.

Therefore, we performed a retrospective study to investigate predictive markers of the development of metachronous and synchronous GC, including GX and endoscopic score for GC risk.

MATERIALS AND METHODS
=====================

Patients
--------

This study was a retrospective, single-center, observational study. Between June 2006 and February 2016, a total of 352 patients underwent ESD for early GC at NTT West Osaka Hospital. Exclusion criteria for this study were as follows: Remnant stomach, unknown *H. pylori* status, and endoscopic observation of the whole stomach outside our hospital. Finally, 192 patients including 109 with solitary GC (Group A) and 83 with metachronous and synchronous GC (Group B), were included in the study (Figure [1](#F1){ref-type="fig"}). Solitary GC was defined as no past history of GC and only one GC that developed during the study period. Metachronous and synchronous GC were defined as a new GC that developed in an area other than the site of primary GC and multiple GC that developed at the same endoscopic examination. The following factors were examined: Age, sex, complicated with diabetes mellitus, complicated with other malignant disease, *H. pylori* status, tumor location, tumor size, macroscopic type, histological type, tumor depth, endoscopic score for GC risk, and presence of severe atrophy, intestinal metaplasia, and GX. Presence of *H. pylori* infection was determined by serum antibody, rapid urease test, immunohistochemistry, ^13^C urea breath test, or stool antigen test. Endoscopic images were evaluated at the time of GC diagnosis or ESD. Endoscopic images were reviewed by one expert endoscopist. We classified the severity of gastric atrophy according to the criteria of Kimura and Takemoto\[[@B21]\]. Severe atrophy was classified as O-2, 3, and P. O-P was the state that gastric atrophy progressed in the whole stomach. We diagnosed presence of GX as yellowish-white flat or slight elevated lesion by white light imaging. Endoscopic score for GC risk was calculated as follows: (1) atrophy: 0 if C-0 and 1, 1 if C-2 and 3, 2 if O-1, 2, 3, and P; (2) intestinal metaplasia: 0 if absent, 1 if present at gastric antrum, 2 if present at gastric antrum and body; (3) fold swelling: 0 if absent, 1 if present; (4) nodular gastritis: 0 if absent, 1 if present; and (5) diffuse redness: 0 if absent, 1 if mild, 2 if severe. For assessment of intestinal metaplasia, image-enhanced endoscopy with distinct white light imaging was necessary. In this study, we evaluated intestinal metaplasia as grayish-white flat elevated lesion by white light imaging, without image-enhanced endoscopy. This study was carried out with the approval of the NTT West Osaka Hospital Ethics Committee. Because of the anonymous nature of the date obtained after each patient had provided written informed consent for ESD, the requirement for informed consent was waived.

![Flow diagram for the study. ESD: Endoscopic submucosal dissection; GC: Gastric cancer.](WJGO-9-327-g001){#F1}

Statistical analysis
--------------------

All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics\[[@B22]\]. Fisher's exact test was performed to investigate the relationships between the two groups. Differences between the two groups were analyzed by Mann-Whitney *U* test when the data was not parametric. Multivariate logistic analysis was used to identify predictive markers of metachronous and synchronous GC. Age, sex, and baseline variates with *P* \< 0.2 in univariate analysis were included in the multivariate logistic analysis. The threshold for significance was *P* \< 0.05.

RESULTS
=======

Clinicopathological characteristics of patients
-----------------------------------------------

The characteristics of the two patient groups are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinicopathological characteristics of the two groups *n* (%)

                                        **Group A (*n* = 109)**   **Group B (*n* = 83)**   ***P* value**
  ------------------------------------- ------------------------- ------------------------ ---------------
  Age, median \[IQR\], yr               66 \[61-74\]              72 \[63-78\]             0.0009
  Male                                  92 (84.4)                 72 (86.7)                0.7
  Diabetes mellitus                     24 (22.0)                 12 (14.5)                0.2
  Complicated other malignant disease   27 (24.8)                 22 (26.5)                0.9
  *Helicobacter pylori* status                                                             0.4
  Positive                              82                        57                       
  Post eradicated                       23                        26                       
  Negative                              4                         0                        
  Tumor location                                                                           0.9
  Upper                                 10                        11                       
  Middle                                57                        39                       
  Lower                                 42                        33                       
  Tumor size, median \[IQR\], mm        15 \[10-20\]              15 \[12-22\]             0.3
  Macroscopic type                                                                         0.5
  0-I                                   9                         3                        
  0-IIa                                 67                        52                       
  0-IIb                                 26                        25                       
  0-IIc                                 7                         3                        
  Differentiated type                   109 (100)                 81 (97.6)                0.2
  Tumor depth                                                                              0.1
  M                                     97                        80                       
  SM                                    12                        3                        

IQR: Interquartile range; M: Mucosal; SM: Submucosal.

The median ages in Group A and B were 66 \[interquartile range (IQR) 61-74\] and 72 (IQR 63-78) years, respectively (*P* = 0.0009). The proportion of male patients was high in both groups (84.4% *vs* 86.7%, *P* = 0.7). *H. pylori* status was positive for many patients in Group A and B (75.2% *vs* 68.7%, respectively, *P* = 0.4).

Regarding tumor location, lesion of the upper part of the stomach was least frequent. Median tumor size was 15 mm in both groups. The most frequent macroscopic type was 0-IIa and the most frequent histological type was the differentiated type.

Endoscopic characteristics
--------------------------

Endoscopic characteristics are shown in Table [2](#T2){ref-type="table"}. Although the difference was not significant, the prevalence of severe atrophy and intestinal metaplasia in Group B tended to be higher than that in Group A (89.2% *vs* 79.8%, *P* = 0.1 and 57.8% *vs* 45.0%, *P* = 0.08). The prevalence of GX in Group B was significantly higher than that in Group A (54.2% *vs* 32.1%, *P* = 0.003). The number and size of GX were not significantly different between the two groups.

###### 

Endoscopic characteristics of the two groups *n* (%)

                          **Group A (*n* = 109)**   **Group B (*n* = 83)**   ***P* value**
  ----------------------- ------------------------- ------------------------ ---------------
  Severe atrophy          87 (79.8)                 74 (89.2)                0.1
  Intestinal metaplasia   49 (45.0)                 48 (57.8)                0.08
  Gastric xanthoma        35 (32.1)                 45 (54.2)                0.003

Endoscopic score for GC risk
----------------------------

The endoscopic score for GC risk is reported in Table [3](#T3){ref-type="table"}. The atrophy score in Group B was significantly higher than that in Group A (*P* = 0.005). The scores for intestinal metaplasia, fold swelling, and diffuse redness, and the total score were not significantly different between the two groups. Nodular gastritis was absent in all patients in this study.

###### 

Endoscopic score of risk for gastric cancer of the two groups

                                **Group A (*n* = 109)**   **Group B (*n* = 83)**   ***P* value**
  ----------------------------- ------------------------- ------------------------ ---------------
  Atrophy                                                                          0.005
  0                             4                         0                        
  1                             6                         0                        
  2                             99                        83                       
  Intestinal metaplasia                                                            0.1
  0                             60                        35                       
  1                             33                        34                       
  2                             16                        14                       
  Fold swelling                                                                    0.6
  0                             99                        73                       
  1                             10                        10                       
  Nodular gastritis                                                                1.0
  0                             109                       83                       
  1                             0                         0                        
  Diffuse redness                                                                  0.5
  0                             4                         0                        
  1                             23                        25                       
  2                             82                        58                       
  Total score, median \[IQR\]   4 \[4-5\]                 4 \[4-5\]                0.1

IQR: Interquartile range.

Multivariate logistic analysis
------------------------------

Age, male sex, severe atrophy, presence of intestinal metaplasia, and presence of GX were subjected to multivariate logistic analysis. As shown in Table [4](#T4){ref-type="table"}, higher age and the presence of GX were independently related to metachronous and synchronous GC.

###### 

Multivariate analysis of predictive marker of metachronous and synchronous gastric cancer

                          **Odds ratio**     ***P* value**
  ----------------------- ------------------ ---------------
  Age                     1.04 (1.01-1.08)   0.02
  Male                    1.38 (0.57-3.34)   0.47
  Severe atrophy          1.68 (0.70-4.05)   0.25
  Intestinal metaplasia   1.35 (0.71-2.54)   0.36
  Gastric xanthoma        2.11 (1.14-3.99)   0.02

DISCUSSION
==========

In the present study, we compared the characteristics of 109 patients with solitary GC to those of 83 patients with metachronous and synchronous GC in order to identify predictive markers for metachronous and synchronous GC. Multivariate logistic analysis revealed that high age and the presence of GX were independently related to metachronous and synchronous GC.

The results of recent studies indicated that male sex, multiple initial GC, severe atrophy, and multiple GC before successful *H. pylori* eradication were independent risk factors for metachronous GC\[[@B13],[@B14]\]. After performing univariate analysis, we carried out multivariate logistic analysis using male sex and severe atrophy as variates, but our results revealed that these two markers were not predictive of metachronous and synchronous GC. This finding may reflect the fact that most patients in this study were male and showed severe atrophy in both groups.

Endoscopic findings related to the development of GC have been previously reported\[[@B23]-[@B27]\]. Of these, five endoscopic findings were confirmed; atrophy, intestinal metaplasia, fold swelling, nodular gastritis, and diffuse redness. A subsequent study reported the endoscopic score for GC risk\[[@B18]\]; however, the usefulness of this score remains unclear. After performing univariate analysis, we carried out multivariate logistic analysis using severe atrophy and intestinal metaplasia as variates. However, our results indicated that these two markers were not predictive of metachronous and synchronous GC. Further investigations are necessary to evaluate the usefulness of the endoscopic score for GC risk.

GX, a localized non-neoplastic accumulation of foamy histiocytes in the lamina propia of the inflamed gastric mucosa, is occasionally found during EGD\[[@B28]\]. GX is a positive indicator of *H. pylori* and persists after *H. pylori* eradication therapy. GX has received little attention clinically, perhaps because it is considered a benign entity\[[@B20]\]. A retrospective cohort study reported that the presence of GX was significantly associated with the presence of GC\[[@B19]\]. Another cohort study performed at the same hospital reported that GX was a useful marker for predicting the development of GC by performing endoscopic follow-up examinations\[[@B20]\]. However, both these studies did not investigate GX as a predictive marker for metachronous and synchronous GC. In our study, univariate analysis revealed that GX was significantly more prevalent in Group B than in Group A. In addition, results of multivariate logistic analysis indicated that GX was a predictive marker for metachronous and synchronous GC. To our knowledge, this is first report of the presence of GX as a useful predictive marker for metachronous and synchronous GC.

Why does GC develop more frequently in patients with GX? Increased release of oxygen free radicals may be involved in the formation of GX\[[@B29]\]. On the other hand, the presence of GX may reflect the severity and long duration of chronic gastritis\[[@B20]\], which is a risk factor for GC development. Because of the same reason, GX may be more frequent in Group B than Group A. However, further studies are required to elucidate this link.

Our study has some limitations. First, it was a retrospective single-center study. Second, the sample size was small. Finally, we did not analyze inter-observer variability in the assessment of endoscopic images.

In summary, our results revealed that higher age and the presence of GX were independently related to metachronous and synchronous GC. These findings, especially the predictive value of the presence of GX, could improve the timely detection and treatment of metachronous and synchronous GC. Further investigations are necessary to confirm the predictive value of these markers.
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